Cervical cancer prevention: The impact of HPV vaccination;Prévention du cancer du col utérin: Enjeux et perspectives de la vaccination antipapillomavirus

Gynecologie Obstetrique et Fertilite

Volumn 34, Issue 3, 2006, Pages 189-201

  Monsonego J ^a  

^a INSTITUT ALFRED FOURNIER   (France)

Author keywords

Cervical cancer; CIN; Condyloma; HPV; Pap test; Papillomavirus; Prevention; Screening; Vaccine

Indexed keywords

NEUTRALIZING ANTIBODY; WART VIRUS VACCINE;

ARTICLE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; COLPOSCOPY; COST CONTROL; FRANCE; HEALTH EDUCATION; HEALTH PROMOTION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LICENSING; PAPANICOLAOU TEST; PRECANCER; PROPHYLAXIS; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS CAPSID; VIRUS PARTICLE; WART VIRUS;

EID: 33645374042     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2006.01.036     Document Type: Article

References (52)

1. Agence nationale pour le d́veloppement de l'́valuation ḿdicale Pratique des frottis cervicaux pour le d́pistage du cancer du col Recommandations et ŕf́rences ḿdicales. Tome 2 1995 Andem Paris 9 24
2. J. Patnick Screening that failed to work E. Franco J. Monsonego New developments in cevical cancer screening and prevention 1997 Blackwell Science Oxford 200 202
3. F.X. Bosch, A. Lorincz, N. Muñoz, C.J.L.M. Meijer, and K.V. Shah The causal relation between human papillomavirus and cervical cancer J. Clin. Pathol. 55 2002 244 265
4. D. Solomon, M. Schiffman, and R. Tarrone Comparison of three management strategies for patients with atypical squamous cells of undetermined significance J. Natl. Cancer Inst. 93 2001 293 299
5. o:5, version 2.0 2004 IARC Press Lyon
6. P. Pisani, D.M. Parkin, F. Bray, and J. Ferlay Estimates of the worldwide mortality from 25 cancers in 1990 Int. J. Cancer. 83 1 (24) Sep 1999 18 29 (Erratum in. Int. J. Cancer 1999;83(6):870-3)
7. Agence nationale d'accŕditation et d'́valuation en sant́ (Anaes) Conduite ̀ tenir devant un frottis anormal du col de l'ut́rus Recommandations pour la pratique clinique. Actualisation 2002 Andem Paris
8. C. Exbrayat Col de l'ut́rus Évolution de l'incidence et de la mortalit́ par cancer en France de 1978 ̀ 2000 2003 INVS Paris 107 112
9. A. Rousseau, P. Bohet, J. Merlìre, H. Treppoz, B. Heules-Bernin, and R. Ancelle-Park Évaluation du d́pistage organiś et du d́pistage individuel du cancer du col de l'ut́rus:: utilit́ des donńes de l'assurance maladie Bull Epidemiol. Hebdo. 19 2002 81 83
10. Council of the European Union Council recommendation of 2 December 2003 on cancer screening Off. J. Eur. Union L327 2003 34 38
11. C. Weidmann, P. Schaffer, G. Hedelin, P. Arveux, G. Chaplain, and C. Exbrayat L'incidence du cancer du col de l'ut́rus ŕgresse ŕgulìrement en France BEH 5 1998 17 19
12. J.M. Walboomers, M.V. Jacobs, M.M. Manos, F.X. Bosch, J.A. Kummer, and K.V. Shah Human papillomavirus is a necessary cause of invasive cervical cancer worldwide J. Pathol. 189 1 1999 12 19
13. E.L. Franco, T.E. Rohan, and L.L. Villa Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer J. Natl. Cancer Inst. 91 6 1999 506 511
14. IARC working group Human papillomavirus. IARC Monographson the evaluation of carcinogenics risk to humans. Vol.64 1995 International agency for research on cancer Lyon
15. L. Koutsky Epidemiology of genital human papillomavirus infection Am. J. Med. 102 5A 1997 3 8
16. M. Schiffman, and S. Krüger Kjaer Natural history of anogenital human papillomavirus infection and neoplasia J. Natl. Cancer Inst. Monogr. 31 2003 14 19
17. E.L. Franco, L.L. Villa, J.P. Sobrinho, J.M. Prado, M.C. Rousseau, and M. D́sy Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer J. Infect. Dis. 180 1999 1415 1423
18. L. Rozendaal, J. Westerga, J.C. van der Linden, J.M. Walboomers, F.J. Voorhorst, and E.K. Risse PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes J. Clin. Pathol. 53 8 2000 606 611
19. P.W. Melkert, E. Hopman, A.J. van den Brule, E.K. Risse, P.J. van Diest, and O.P. Bleker Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent Int. J. Cancer 53 6 1993 919 923
20. G.M. Clifford, S. Gallus, R. Herrero, N. Munoz, P.J. Snijders, S. Vaccarella IARC HPV Prevalence Surveys Study Group Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis Lancet 366 9490 Sep 2005 991 998 (17-23)
21. G.M. Clifford, R.K. Rana, S. Franceschi, J.S. Smith, G. Gough, and J.M. Pimenta Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer Cancer Epidemiol. Biomarkers Prev. 14 5 2005 1157 1164 (Review)
22. G.M. Clifford, J.S. Smith, T. Aguado, and S. Franceschi Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis Br. J. Cancer 89 1 2003 101 105
23. M.J. Khan, P.E. Castle, A.T. Lorincz, S. Wacholder, M. Sherman, and D.R. Scott The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice J. Natl. Cancer Inst. 97 14 2005 1072 1079
24. P.E. Castle, D. Solomon, M. Schiffman, and M. Cosette Wheeler for the ALTS group. human papillomavirus type 16 infections and 2-Year absolute risk of cervical precancer in Women with equivocal or mild cytologic abnormalities J. Natl. Cancer Inst. 97 2005 1066 1071
25. L.A. Koutsky, K.K. Holmes, C.W. Critchlow, C.E. Stevens, J. Paavonen, and A.M. Beckmann A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection N. Engl. J. Med. 327 18 1992 1272 1278
26. G.Y. Ho, R.D. Burk, S. Klein, A.S. Kadish, C.J. Chang, and P. Palan Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia J. Natl. Cancer Inst. 87 1995 1365 1371
27. V. Dalstein, D. Riethmuller, J.L. Pretet, K. Le Bail Carval, J.L. Sautiere, and J.P. Carbillet Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study Int. J. Cancer 106 3 2003 396 403
28. J.P. Bory, J. Cucherousset, M. Lorenzato, R. Gabriel, C. Quereux, and P. Birembaut Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women Int. J. Cancer 102 5 2002 519 525
29. N.F. Schlecht, S. Kulaga, J. Robitaille, S. Ferreira, M. Santos, and R.A. Miyamura Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia JAMA 286 2001 3106 3114
30. K.L. Wallin, F. Wiklund, T. Angstrom, F. Bergman, U. Stendahl, and G. Wadell Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer N. Engl. J. Med. 341 22 1999 1633 1638
31. S.S. Wang, and A. Hildesheim Viral and host factors in human papillomavirus persistence and progression J. Natl. Cancer Inst. Monogr. 31 2003 35 40
32. J. Monsonego Papillomavirus et cancer du col de l'ut́rus Med. Sci. (Paris) 12 1996 733 744
33. S. Chellappan, V.B. Kraus, B. Kroger, K. Munger, P.M. Howley, and W.C. Phelps Adenovirus E1A, simian virus 40 tumors antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product Proc. Natl. Acad. Sci. USA 89 10 1992 4549 4553
34. M. Thomas, G. Matlashewski, D. Pim, and L. Banks Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation Oncogene 13 2 1996 265 273
35. L.A. Koutsky, K.A. Ault, C.M. Wheeler, D.R. Brown, E. Barr, F.B. Alvarez Proof of Principle Study Investigators A controlled trial of a human papillomavirus type 16 vaccine N. Engl. J. Med. 347 21 2002 1645 1651
36. L.L. Villa, R.L. Costa, C.A. Petta, R.P. Andrade, K.A. Ault, and A.R. Giuliano Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial Lancet Oncol. 6 5 2005 271 278
37. D.M. Harper, E.L. Franco, C. Wheeler, D.G. Ferris, D. Jenkins, A. Schuind GlaxoSmithKline HPV Vaccine Study Group Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial Lancet 364 9447 Nov 2004 1757 1765 (13-19)
38. N. Munoz, F.X. Bosch, X. Castellsague, M. Diaz, S. de Sanjose, and D. Hammouda Against which human papillomavirus types shall we vaccinate and screen? The international perspective Int. J. Cancer 111 2 2004 278 285
39. S.J. Goldie, D. Grima, M. Kohli, T.C. Wright, M. Weinstein, and E. Franco A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine Int. J. Cancer 106 6 2003 896 904
40. K. Huang, and S. Lin Nationwide vaccination: a success story in Taiwan Vaccine 18 Suppl 1 2000 S35 S38
41. S.J. Goldie, M. Kohli, D. Grima, M.C. Weinstein, T.C. Wright, and F.X. Bosch Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine J. Natl. Cancer Inst. 96 8 2004 604 615
42. G.D. Sanders, and A.V. Taira Cost-effectiveness of a potential vaccine for human papillomavirus Emerg. Infect. Dis. 9 1 2003 37 48
43. S.L. Kulasingam, and E.R. Myers Potential health and economic impact of adding a human papillomavirus vaccine to screening programs JAMA 290 6 2003 781 789
44. M. Bozon At what age do women and men have their first sexual intercourse? World comparisons and recent trends Popul. Soc. (Paris) 391 2003 1 4
45. R. Anhang, T.C. Wright Jr., L. Smock, and S.J. Goldie Women's desired information about human papillomavirus Cancer 100 2 2004 315 320
46. R. Anhang, J.E. Stryker, T.C. Wright Jr., and S.J. Goldie News media coverage of human papillomavirus Cancer 100 2 2004 308 314
47. S.W. Duffy, L. Tabar, H.H. Chen, M. Holmqvist, M.F. Yen, and S. Abdsalah The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties Cancer 95 3 2002 458 469
48. S.A. Feig Effect of service screening mammography on population mortality from breast carcinoma Cancer 95 3 2002 451 457
49. J. Monsonego Spontaneous screening: benefits and limitations E. Franco J. Monsonego New developments in cervical cancer screening and prevention 1997 Blackwell Science Oxford 220 240
50. J. Monsonego Enqûte nationale sur le d́pistage du cancer du col aupr̀s des gyńcologues Gynecol. Obstet. Pratique 81 1996 1 5
51. S. Camatte, P. Morice, P. Pautier, C. Lhomḿ, C. Haie-Maider, and P. Duvillard B. Blanc Incidence et mortalit́ du cancer du col en France. Quelle relation avec le d́pistage 2005 Springer Paris 35 45
52. G.P. Garnett, and H.C. Waddell Public health paradoxes and the epidemiological impact of an HPV vaccine J. Clin. Virol. 19 1-2 2000 101 111 (Review)